Vasculopathy, Inflammation and Systemic Sclerosis (VISS)
Primary Purpose
Systemic Sclerosis
Status
Completed
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Blood samples
Biopsy
Sponsored by
About this trial
This is an interventional other trial for Systemic Sclerosis focused on measuring T lymphocyte, OX40/OX40L
Eligibility Criteria
Inclusion Criteria:
- Age from 18 to 75.
- SSc diagnosed according to the American College of Rheumatology (ACR) criteria.
- With skin manifestations since less than 10 years.
- Localised sclerosis (LSc) diagnosed, morphea type.
Exclusion Criteria:
- Age inferior to 18 or upper than 75.
- Skin manifestations since more than 10 years.
- Haemostasis diseases (independent from treatments).
- Stem cell transplant.
- Immunosuppressive treatments in the last 6 months.
- Associate autoimmune disease.
Sites / Locations
- Service de Rhumatologie - Tripode - Hôpital Pellegrin
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Experimental
Experimental
Arm Label
subjects SSc diagnosed
subjects Localised sclerosis diagnosed
subjects Sc
Arm Description
Outcomes
Primary Outcome Measures
Assessment of OX40L expression in endothelial cells and skin biopsies.
Secondary Outcome Measures
Full Information
NCT ID
NCT02562079
First Posted
December 29, 2014
Last Updated
April 5, 2017
Sponsor
University Hospital, Bordeaux
Collaborators
Societe Francaise de Rhumatologie
1. Study Identification
Unique Protocol Identification Number
NCT02562079
Brief Title
Vasculopathy, Inflammation and Systemic Sclerosis
Acronym
VISS
Official Title
Vasculopathy, Inflammation and Systemic Sclerosis: The Role of Endothelial Cell Activation and OX40/OX40L in Modulation of T Lymphocyte Activation
Study Type
Interventional
2. Study Status
Record Verification Date
April 2017
Overall Recruitment Status
Completed
Study Start Date
March 2012 (Actual)
Primary Completion Date
December 2016 (Actual)
Study Completion Date
December 2016 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Bordeaux
Collaborators
Societe Francaise de Rhumatologie
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
It is a study of basic research with mechanistically objectives and including clinical biological samples.
Detailed Description
Systemic sclerosis (SSc) is a rare and severe disease characterised by a fibrotic process and an incompletely elucidate physiopathology. Several shared featured have been identified between SSc and another autoimmune disease, the systemic lupus erythematous (SLE) as an interferon-alpha signature, the role of platelets and the polymorphism of OX40 ligand (OX40L). In SLE, OX40L has been shown highly linked to the active form of the disease, was increased by the CD40L of platelets and induced the CD8 cytotoxicity while inhibiting the suppressive functions of regulator T lymphocytes. The third main factor of the SSc physiopathology apart from autoimmunity and fibrosis is the vasculopathy with an important role of endothelial cells (EC). They turned out to be half-professional antigen presenting cells and can modulate the adaptive immunity.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Systemic Sclerosis
Keywords
T lymphocyte, OX40/OX40L
7. Study Design
Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
350 (Actual)
8. Arms, Groups, and Interventions
Arm Title
subjects SSc diagnosed
Arm Type
Experimental
Arm Title
subjects Localised sclerosis diagnosed
Arm Type
Experimental
Arm Title
subjects Sc
Arm Type
Experimental
Intervention Type
Biological
Intervention Name(s)
Blood samples
Intervention Description
biological features of the standard follow-up
2 more blood tube for the biological collection (serum and PBMC)
Intervention Type
Biological
Intervention Name(s)
Biopsy
Intervention Description
Skin biopsies
Primary Outcome Measure Information:
Title
Assessment of OX40L expression in endothelial cells and skin biopsies.
Time Frame
Day 1
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age from 18 to 75.
SSc diagnosed according to the American College of Rheumatology (ACR) criteria.
With skin manifestations since less than 10 years.
Localised sclerosis (LSc) diagnosed, morphea type.
Exclusion Criteria:
Age inferior to 18 or upper than 75.
Skin manifestations since more than 10 years.
Haemostasis diseases (independent from treatments).
Stem cell transplant.
Immunosuppressive treatments in the last 6 months.
Associate autoimmune disease.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Marie-Elise TRUCHETET, MD
Organizational Affiliation
University Hospital Bordeaux, France
Official's Role
Principal Investigator
Facility Information:
Facility Name
Service de Rhumatologie - Tripode - Hôpital Pellegrin
City
Bordeaux
ZIP/Postal Code
33076
Country
France
12. IPD Sharing Statement
Learn more about this trial
Vasculopathy, Inflammation and Systemic Sclerosis
We'll reach out to this number within 24 hrs